DataMeds AI Terminates Second Amended LOI With Datavault AI And Partners Due To Market Conditions; No Shares To Be Issued Under LOI, Existing REBOOT And Datavault Agreements Remain In Effect; Co Does Not Owe Any Fees Or Obligation As A Result Of The Termination

DataMeds AI, Inc. ("DataMeds SI," "DataMEDS" or the "Company") (NASDAQ:MEDS), a healthcare company that integrates its health information technology and physical infrastructure with its EinsteinRx™ artificial intelligence platform and PharmacyChain™ blockchain-enabled smart contracts platform, today announced that it has terminated the Second Amended and Restated letter of intent dated October 19, 2026 ("2nd LOI") with Datavault AI Inc. ("Datavault AI") (NASDAQ:DVLT), Data Health Partners, Inc.'s ("DHP") wholly-owned subsidiary REBOOT Health AI, Inc., EOS Technology Holdings, Inc. ("EOS"), Scilex Holding Company ("Scilex") and HealthBridge Advisors, LLC ("HealthBridge Advisors") for the in-license or acquisition of IP in exchange for Company common stock due to market conditions. DataMEDS does not owe any fees or obligation as a result of the termination.

As a result of the termination of the 2nd LOI, DataMEDS will no longer be issuing any shares related to the 2nd LOI.

DataMEDS confirms that its exclusive license with REBOOT for the management of GLP-1 users, dated October 13, 2026, remains in full force and effect.

Datavault AI for PharmacyChain™ manufacturer-to-patient blockchain-enabled smart contracts remains in full force and effect, in accordance with the terms of that agreement dated November 24, 2025. No shares of the Company were issued to Datavault in connection with that agreement.